PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways-Reference-Cited by-同舟云学术

PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways

Published:2019-12 Issue:6 Volume:51 Page:1059-1073.e9
ISSN:1074-7613
Container-title:Immunity
language:en
Short-container-title:Immunity

Author:

Zhao Yunlong,Lee Calvin K.,Lin Chia-Hao,Gassen Rodrigo B.,Xu Xiaozheng,Huang Zhe,Xiao Changchun,Bonorino Cristina,Lu Li-Fan,Bui Jack D.,Hui Enfu^ORCID

Funder

NINDS P30 Grant

Cancer Research Institute Irvington Postdoctoral Fellow

UCSD Cancer Biology Postdoctoral Fellowship

CAPES

CNPq Productivity Fellowship

Kinship Foundation

Pew Charitable Trusts

NIH

Hartwell Foundation

Publisher

Elsevier BV

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference66 articles.

1. Regulation of surface and intracellular expression of CTLA4 on mouse T cells;Alegre;J. Immunol.,1996

2. Different cell surface oligomeric states of B7-1 and B7-2: implications for signaling;Bhatia;Proc. Natl. Acad. Sci. USA,2005

3. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer;Brahmer;N. Engl. J. Med.,2012

4. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses;Butte;Immunity,2007

5. Interaction of human PD-L1 and B7-1;Butte;Mol. Immunol.,2008

Cited by 251 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A general pHLA-CD80 scaffold fusion protein to promote efficient antigen-specific T cell-based immunotherapy;Molecular Therapy: Oncology;2024-09

2. Rigid, bivalent CTLA-4 binding to CD80 is required to disrupt the cis CD80/PD-L1 interaction;Cell Reports;2024-09

3. Expression, regulation, and function of PD-L1 on non-tumor cells in the tumor microenvironment;Drug Discovery Today;2024-09

4. Lymphatic system regulation of anti-cancer immunity and metastasis;Frontiers in Immunology;2024-08-15

5. First-line treatment with KN046, chemotherapy and palliative radiotherapy for advanced esophageal squamous cell carcinoma: an open-label, dose escalation, and dose expansion phase Ib trial;Cancer Immunology, Immunotherapy;2024-08-06